Clinical Monograph • Medically Reviewed
Lipitor
Atorvastatin Calcium • HMG-CoA Reductase Inhibitor (Statin)
Clinical Overview: High-intensity statin therapy engineered to competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A reductase, catalyzing the rate-limiting step in hepatic cholesterol synthesis.
Therapeutic Indications & Pharmacodynamics
Atorvastatin delivers robust dose-dependent LDL-C reductions ranging from 39% to 60%, significant apolipoprotein B lowering, and modest HDL-C elevation. Proven in landmark clinical trials (ASCOT-LLA, CARDS, PROVE-IT) to reduce major adverse cardiovascular events (MACE), myocardial infarction, and stroke.
Clinical Indications
Primary hyperlipidemia, mixed dyslipidemia, familial hypercholesterolemia, secondary prevention of cardiovascular events in ASCVD patients.
Contraindications & Precautions
Active liver disease, unexplained persistent hepatic transaminase elevations, pregnancy, and hypersensitivity.
Prescribing Profile
Available Strengths:
10mg, 20mg, 40mg, 80mg
10mg, 20mg, 40mg, 80mg
Elimination Half-Life:
14 hours (active inhibitory metabolites extend functional duration to 20–30 hours)
14 hours (active inhibitory metabolites extend functional duration to 20–30 hours)
Reviewing Physician:
Dr. Caroline Hernandez, MD
Dr. Caroline Hernandez, MD
Institutional Dosing Monograph